Patricia S Andrews
CIK 1445710 · Chief Commercial Officer · last filed 2026-06-03
Patricia S Andrews is a Chief Commercial Officer who has filed 21 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for ONCY, was dated Jun 3, 2026. Across all open-market trades the lifetime net is +$112.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $62.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$62.7K
4
21
$112.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONCY | Director | 78,128 | $0.80 | $62.7K | $30.3K | 2 | 2026-06-03 |
| GERN | Director | — | $1.15 | — | $0 | 1 | 2026-03-26 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 58,608 | $15.70 | $920.1K | $82.0K | 11 | 2024-05-01 |
| INCY | Chief Commercial Officer | — | $108.53 | — | $0 | 7 | 2012-01-23 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | ONCY | Grant (A) | — | $0 | EDGAR |
| 2026-03-26 | GERN | Grant (A) | — | $0 | EDGAR |
| 2026-02-13 | ONCY | Buy (P) | +35,400 | $30.3K | EDGAR |
| 2024-05-01 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-02 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +5,191 | $12.3K | EDGAR |
| 2023-10-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +8,167 | $12.3K | EDGAR |
| 2023-05-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-20 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-18 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +40,000 | $82.0K | EDGAR |
| 2021-05-27 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +5,250 | $0 | EDGAR |